CXCR2 and thyroid gland carcinoma: Recent reviews also suggest that CXCR2 is a central regulator of both cancer progression and inflammation, and CXCR2 antagonists such as SB225002 showed potential as therapeutic agents due to their capacity to prevent myeloid-derived suppressor cell (MDSC) recruitment and facilitate immune responses in prostate, hepatocellular, lung, and thyroid cancers in preclinical studies [48].